S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Veeva Systems (VEEV) Stock Price, News & Analysis

$198.38
-1.16 (-0.58%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$197.03
$199.65
50-Day Range
$198.37
$234.79
52-Week Range
$160.21
$236.90
Volume
735,400 shs
Average Volume
985,182 shs
Market Capitalization
$32.00 billion
P/E Ratio
61.61
Dividend Yield
N/A
Price Target
$234.90

Veeva Systems MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.65 Rating Score
Upside/​Downside
18.4% Upside
$234.90 Price Target
Short Interest
Healthy
1.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
0.81mentions of Veeva Systems in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$4.40 M Sold Last Quarter
Proj. Earnings Growth
14.36%
From $4.11 to $4.70 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.78 out of 5 stars

Computer And Technology Sector

50th out of 586 stocks

Prepackaged Software Industry

14th out of 201 stocks

VEEV stock logo

About Veeva Systems Stock (NYSE:VEEV)

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

VEEV Stock Price History

VEEV Stock News Headlines

How Is The Market Feeling About Veeva Systems?
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Veeva Launches AI Partner Program
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Veeva Announces Vault CRM Campaign Manager
Veeva Systems (NYSE:VEEV) Upgraded at StockNews.com
Is Veeva Systems (VEEV) a Good Investment Bet?
See More Headlines
Receive VEEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veeva Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/21/2024
Next Earnings (Estimated)
5/29/2024
Fiscal Year End
1/31/2025

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Employees
7,172
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$234.90
High Stock Price Target
$270.00
Low Stock Price Target
$160.00
Potential Upside/Downside
+18.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
20 Analysts

Profitability

Net Income
$525.71 million
Pretax Margin
24.88%

Debt

Sales & Book Value

Annual Sales
$2.36 billion
Cash Flow
$3.49 per share
Book Value
$28.80 per share

Miscellaneous

Free Float
143,604,000
Market Cap
$32.00 billion
Optionable
Optionable
Beta
0.74

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy Veeva Systems Stock? VEEV Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Veeva Systems Inc.:

  • Veeva Systems provides cloud-based software tailored for the life sciences industry, offering solutions like Veeva Commercial Cloud and Veeva Vault PromoMats, catering to the specific needs of pharmaceutical and biotechnology companies.
  • Veeva's suite of software includes Veeva customer relationship management (CRM) which enables customer-facing employees to enhance interactions with clients, potentially leading to increased sales and customer satisfaction.
  • The company's focus on analytics solutions like Veeva Crossix and Veeva OpenData can provide valuable insights for pharmaceutical brands, aiding in strategic decision-making and market positioning.
  • Veeva's diverse product offerings, such as Veeva Vault Medical and Veeva Link, showcase the company's commitment to innovation and addressing the evolving needs of the life sciences industry.
  • Considering the recent positive market sentiment towards Veeva Systems, reflected in its stock price performance, investors may find potential for capital appreciation and returns on their investment.

Cons

Investors should be bearish about investing in Veeva Systems Inc. for these reasons:

  • While Veeva Systems has shown strong performance, the competitive landscape in the cloud-based software industry, especially in the life sciences sector, could pose challenges for sustained growth and market share expansion.
  • Market volatility and fluctuations in the technology sector may impact Veeva's stock price, potentially leading to short-term uncertainties for investors.
  • Regulatory changes or shifts in the healthcare industry could affect Veeva's business operations and product demand, introducing risks related to compliance and market dynamics.
  • Investors should carefully assess Veeva's financial metrics, market positioning, and growth strategies to ensure alignment with their investment objectives and risk tolerance.
  • External factors like global economic conditions or geopolitical events may influence Veeva Systems' performance and stock price, requiring investors to stay informed and proactive in their investment decisions.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Veeva Systems pros and cons to contact@marketbeat.com.

VEEV Stock Analysis - Frequently Asked Questions

Should I buy or sell Veeva Systems stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veeva Systems in the last year. There are currently 1 sell rating, 5 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VEEV shares.
View VEEV analyst ratings
or view top-rated stocks.

What is Veeva Systems' stock price target for 2024?

20 analysts have issued 12-month target prices for Veeva Systems' stock. Their VEEV share price targets range from $160.00 to $270.00. On average, they predict the company's share price to reach $234.90 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for VEEV
or view top-rated stocks among Wall Street analysts.

How have VEEV shares performed in 2024?

Veeva Systems' stock was trading at $192.52 on January 1st, 2024. Since then, VEEV shares have increased by 3.0% and is now trading at $198.38.
View the best growth stocks for 2024 here
.

When is Veeva Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 29th 2024.
View our VEEV earnings forecast
.

How were Veeva Systems' earnings last quarter?

Veeva Systems Inc. (NYSE:VEEV) released its earnings results on Thursday, February, 29th. The technology company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.81 by $0.11. The technology company had revenue of $630.62 million for the quarter, compared to analysts' expectations of $620.75 million. Veeva Systems had a net margin of 22.24% and a trailing twelve-month return on equity of 11.26%.

What guidance has Veeva Systems issued on next quarter's earnings?

Veeva Systems updated its first quarter 2025 earnings guidance on Friday, April, 19th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $640.0 million-$643.0 million, compared to the consensus revenue estimate of $641.9 million.

What is Peter Gassner's approval rating as Veeva Systems' CEO?

202 employees have rated Veeva Systems Chief Executive Officer Peter Gassner on Glassdoor.com. Peter Gassner has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Veeva Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veeva Systems investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), PayPal (PYPL), Shopify (SHOP), Walt Disney (DIS), Adobe (ADBE), Netflix (NFLX), Trade Desk (TTD) and Block (SQ).

Who are Veeva Systems' major shareholders?

Veeva Systems' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.46%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Los Angeles Capital Management LLC (0.09%), Rockland Trust Co. (0.06%), Thomasville National Bank (0.05%) and Gateway Investment Advisers LLC (0.03%). Insiders that own company stock include Alan Mateo, Eleni Nitsa Zuppas, Jonathan Faddis, Joseph Christopher Hays, Mary Lynne Hedley, Matthew J Wallach, Matthew J Wallach, Michele O'connor, Paul Edward Chamberlain, Paul J Sekhri, Peter P Gassner, Ronald E F Codd, Steven L Fasman, Thomas D Schwenger and Timothy S Cabral.
View institutional ownership trends
.

How do I buy shares of Veeva Systems?

Shares of VEEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Veeva Systems have any subsidiaries?
The following companies are subsidiares of Veeva Systems: AdvantageMS, Learnaboutgmp, Physicians World, Selligy, Veeva Crossix, Veeva RTSM, Veracity Logic, and Zinc Ahead Ltd.
Read More
This page (NYSE:VEEV) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners